Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 603 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01775072Recruiting
Genetic testing using stored or new cancer samples
This study collects and analyzes genetic information from tissue or blood samples to help understand cancer and related inherited (family) risk. It may involve testing results being shared with you or your care team, depending on what samples are available.
Bridgeport, ConnecticutAges Any age - NCT01728402Enrolling by invitation
Study of the causes of certain blood cancers
This study looks at what leads to specific blood cancers and related blood disorders. If you have one of the listed conditions (or are being evaluated for it), you may be asked to join research that helps doctors understand why these illnesses happen.
Portland, OregonAges 1 year+ - NCT07406139RecruitingPhase 4
PCC treatment for hemophilia A with inhibitors
This trial tests a clotting factor product called PCC (prothrombin complex concentrate) to treat bleeding episodes in people with hemophilia A who have developed inhibitors. It's for those who are 12–65 and have frequent joint bleeds.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT07413991Recruiting
Writing program for young adults with blood cancer
This trial studies whether expressive writing can help young adults with blood cancer and their caregivers. It is a remote program for people in the U.S. or Canada.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07440485Recruiting
Aspergillus infection study for hematology patients
This study looks at Aspergillus infections in people admitted to the hematology ward. It aims to understand how common these infections are and how they affect patients.
Pavia, PaviaAges 18 years+ - NCT07441525RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat autoimmune blood diseases
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Wuhan, HubeiAges 18–75 - NCT07441993RecruitingPhase 2
Orelabrutinib for early-stage untreated marginal zone lymphoma
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07445438Recruiting
A multi-omics study for blood cancers
This study is testing whether a complete platform that analyzes multiple molecular levels (multi-omics) can be used to better understand and diagnose blood cancers (hematological malignancies). It looks at samples from the blood, bone marrow, and tissues to help with initial diagnosis or when cancer returns after treatment.
Parma, PRAges 2 years+ - NCT07445984Recruiting
Gene testing for blood cancer patients
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
Parma, PRAges 1 year+ - NCT07454226Recruiting
Drug combo for Ph-like acute lymphoblastic leukemia
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07461116Recruiting
Side effects of ATG/ALG treatment for aplastic anemia
This study looks at the side effects of a medicine called ATG or ALG, which is given to calm the immune system in people with aplastic anemia. It may help doctors better understand and manage these side effects.
TianjinAges Any age - NCT07471516RecruitingPhase 1/Phase 2
Zoledronic acid for congenital dyserythropoietic anemia
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
TianjinAges 18 years+ - NCT07472972Recruiting
Personalized risk tracking for CD19 CAR T therapy
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
Zurich, Canton of ZurichAges Any age - NCT07477912RecruitingPhase 1/Phase 2
BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
MinskAges 18 years+ - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT05952804RecruitingPhase 2
IVIG to help prevent infections after CAR-T treatment
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
Duarte, CaliforniaAges 18 years+ - NCT07596823Recruiting
Blood counts and nerve pain relief after a nerve block
This study looks at how blood cell counts change when you receive a nerve-blocking injection for neuropathic pain (nerve damage pain). Researchers want to understand if these blood changes can predict how well the injection will help your pain.
Ankara, CankayaAges 18 years+ - NCT07493538RecruitingPhase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Minneapolis, MinnesotaAges 2–75 - NCT07511127RecruitingPhase 3
Maribavir for stubborn CMV after stem cell transplant
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
ShanghaiAges 18–75 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07532824RecruitingPhase 1/Phase 2
Proton Radiation and Stem Cell Transplant for High-Risk Blood Cancers
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
PragueAges 18–65 - NCT07543159Recruiting
Blood and tissue sample collection for medical research
This study collects blood, tissue, or other samples from people with various conditions—including cancer, infections, autoimmune diseases, or healthy volunteers—to help researchers understand these diseases better. Your samples will be stored and used for future medical research.
Shirley, New YorkAges 18 years+ - NCT07555470RecruitingPhase 2
New drugs for follicular lymphoma: mosunetuzumab and zeprumetostat
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 603 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.